Nevertheless, inhibitors of VEGF‐A–VEGFR2 signaling could reduce the sizes of thyroid goiter, thus providing a novel therapeutic concept of targeting vasculatures in these TSHR‐associated diseases such as Graves' disease and warranting further clinical investigation. This evidence concerns the gene KDR and Graves disease.